Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 8:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–22 of 22 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Ventilator Associated Bacterial Pneumonia Clear all
Completed No phase listed Observational

Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae

NCT02420366
View directory record Official record
Conditions
Urinary Tract Infection, Complicated, Acute Pyelonephritis, Hospital Acquired Bacterial Pneumonia, Ventilator-associated Bacterial Pneumonia, Bacteremia
Interventions
Not listed
Lead sponsor
Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)
Industry
Eligibility
18 Years and older
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
12
States / cities
Chicago, Illinois • Evanston, Illinois • Detroit, Michigan + 8 more
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced Jul 21, 2026, 8:53 PM EDT
Completed No phase listed Observational

Telavancin Observational Use Registry (TOUR)

NCT02288234
View directory record Official record
Conditions
Hospital Acquired Bacterial Pneumonia, Complicated Skin and Skin Structure Infections, Ventilator Associated Bacterial Pneumonia, Gram Positive Infection
Interventions
Vibativ
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
1,063 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Southfield, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 14, 2019 · Synced Jul 21, 2026, 8:53 PM EDT
Completed No phase listed Observational

Study to Determine Quicker Methods of Diagnosing Pneumonia Caused by a Breathing Machine in Critically Ill Patients

NCT00938002
View directory record Official record
Conditions
Ventilator Acquired Pneumonia
Interventions
Acceler8 Pheno
Diagnostic Test
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 23, 2019 · Synced Jul 21, 2026, 8:53 PM EDT
Terminated Phase 2 Interventional Results available

Prevention of S. Aureus Pneumonia Study in Mechanically Ventilated Subjects Who Are Heavily Colonized With S. Aureus.

NCT02940626
View directory record Official record
Conditions
Pneumonia, Ventilator-associated, Pneumonia, Staphylococcal
Interventions
ASN100, Placebo
Drug
Lead sponsor
Arsanis, Inc.
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
17
States / cities
Phoenix, Arizona • Sacramento, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced Jul 21, 2026, 8:53 PM EDT
Recruiting Phase 1 Interventional

A Study to Assess Sulbactam-durlobactam in Pediatric Patients With Acinetobacter Baumannii-calcoaceticus Complex Infection

NCT06801223
View directory record Official record
Conditions
Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC)
Interventions
Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours), Sulbactam 20mg/kg-Durlobactam 20mg/kg (Every 8 hours), Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 8 hours), Sulbactam 20mg/kg-Durlobactam 20mg/kg (Every 12 hours)
Drug
Lead sponsor
Innoviva Specialty Therapeutics
Industry
Eligibility
1 Day to 18 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
4
States / cities
Los Angeles, California • San Diego, California • Greenville, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Jul 21, 2026, 8:53 PM EDT
Terminated Phase 2 Interventional Results available

Study Evaluating Safety and Efficacy of Tigecycline Versus Imipenem/Cilastatin Subjects With Hospital-Acquired Pneumonia

NCT00707239
View directory record Official record
Conditions
Pneumonia, Bacterial
Interventions
tigecycline, imipenem/cilastatin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
3
States / cities
Louisville, Kentucky • Omaha, Nebraska • Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Jul 9, 2012 · Synced Jul 21, 2026, 8:53 PM EDT
Terminated Phase 3 Interventional

Pivotal Study in VAP Suspected or Confirmed to be Due to Pseudomonas Aeruginosa

NCT03409679
View directory record Official record
Conditions
Pneumonia
Interventions
Murepavadin, Two anti-pseudomonal antibiotics
Drug
Lead sponsor
Polyphor Ltd.
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Chicago, Illinois • Springfield, Missouri • Greensboro, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Jul 21, 2026, 8:53 PM EDT
Completed Phase 2 Interventional Results available

An Effectiveness, Safety, and Microbiology Study of Doripenem in Patients With Nosocomial (Hospital-acquired) Pneumonia

NCT00502801
View directory record Official record
Conditions
Pneumonia, Bacterial Pneumonia, Ventilator-Associated Pneumonia, Infections, Nosocomial
Interventions
doripenem
Drug
Lead sponsor
PriCara, Unit of Ortho-McNeil, Inc.
Industry
Eligibility
18 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
24
States / cities
Palm Springs, California • San Francisco, California • Denver, Colorado + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2013 · Synced Jul 21, 2026, 8:53 PM EDT
Recruiting No phase listed Observational

A Study to Assess the Safety and Risk of Hypersensitivity Reactions of Sulbactam-durlobactam in Adults With Acinetobacter Baumannii-calcoaceticus (ABC) Complex Infection

NCT06746883
View directory record Official record
Conditions
Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC)
Interventions
Non-interventional
Other
Lead sponsor
Innoviva Specialty Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
12
States / cities
Sacramento, California • Gainesville, Florida • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Jul 21, 2026, 8:53 PM EDT
Completed Phase 2 Interventional

Aerosolized Antibiotics and Respiratory Tract Infection in Patients on Mechanical Ventilation

NCT00396578
View directory record Official record
Conditions
Ventilator Associated Pneumonia, Respiratory Infection, Tracheobronchitis
Interventions
aerosolized vancomycin or gentamicin
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Nov 6, 2006 · Synced Jul 21, 2026, 8:53 PM EDT
Completed No phase listed Observational

Pharmacodynamic Parameters of Two Different Doses of Cefepime

NCT00177736
View directory record Official record
Conditions
Infection, Bacteremia, Pneumonia
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 12, 2007 · Synced Jul 21, 2026, 8:53 PM EDT
Completed No phase listed Observational

MASTERMIND-Pneumonia Study (Also Known as Pneumonia Direct Pilot)

NCT06181669
View directory record Official record
Conditions
Pneumonia, Bacterial, Ventilator Associated Pneumonia
Interventions
Pathogen and Host Directed testing
Diagnostic Test
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
4
States / cities
Detroit, Michigan • Royal Oak, Michigan • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Jul 21, 2026, 8:53 PM EDT
Completed Phase 2 Interventional

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Pediatric Participants

NCT04215991
View directory record Official record
Conditions
Gram-negative Bacterial Infections, Hospital Acquired Bacterial Pneumonia (HABP), Complicated Urinary Tract Infection (cUTI), Ventilator Associated Bacterial Pneumonia (VABP)
Interventions
Cefiderocol, Standard of Care
Drug
Lead sponsor
Shionogi
Industry
Eligibility
3 Months to 17 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Iowa City, Iowa • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated May 24, 2025 · Synced Jul 21, 2026, 8:53 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex

NCT03894046
View directory record Official record
Conditions
Acinetobacter Baumannii-calcoaceticus Complex, Hospital-acquired Bacterial Pneumonia, Ventilator-associated Bacterial Pneumonia, Bacteremia, Colistin Resistant ABC
Interventions
Sulbactam, Durlobactam, Colistin, Imipenem/Cilastatin 500 mg/500 mg
Drug
Lead sponsor
Entasis Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
5
States / cities
Chicago, Illinois • Shreveport, Louisiana • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2023 · Synced Jul 21, 2026, 8:53 PM EDT
Completed Phase 3 Interventional Results available

Clinical Study of Cefiderocol (S-649266) for the Treatment of Nosocomial Pneumonia Caused by Gram-negative Pathogens

NCT03032380
View directory record Official record
Conditions
Healthcare-associated Pneumonia (HCAP), Hospital Acquired Pneumonia (HAP), Ventilator Associated Pneumonia (VAP)
Interventions
Cefiderocol, Meropenem, Linezolid
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
15
States / cities
New Haven, Connecticut • DeLand, Florida • Chicago, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2020 · Synced Jul 21, 2026, 8:53 PM EDT
Completed Phase 2 Interventional

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Neonates and Infants

NCT06086626
View directory record Official record
Conditions
Gram-Negative Bacterial Infections
Interventions
Cefiderocol, Standard of Care
Drug
Lead sponsor
Shionogi
Industry
Eligibility
Up to 3 Months
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Little Rock, Arkansas • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Jul 21, 2026, 8:53 PM EDT
Completed Early Phase 1 Interventional

Reduction of Bacterial Resistance With Inhaled Antibiotics in the Intensive Care Unit

NCT01878643
View directory record Official record
Conditions
Respiratory Infection, Bacterial Resistance, Respiratory Failure
Interventions
vancomycin or gentamicin, Placebo
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Jun 16, 2013 · Synced Jul 21, 2026, 8:53 PM EDT
Completed No phase listed Observational

CTTI Risk Factors for HABP/VABP Study

NCT02689531
View directory record Official record
Conditions
Pneumonia, Ventilator-Associated, Pneumonia, Bacterial, Pneumonia, Hospital-Acquired
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
7,530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced Jul 21, 2026, 8:53 PM EDT
Terminated Phase 2 Interventional Results available

Clinical Trials to Reduce the Risk of Antimicrobial Resistance

NCT01570192
View directory record Official record
Conditions
Bacterial Pneumonia
Interventions
IV meropenem, I.V. Meropenem, Parenteral aminoglycoside; tobramycin for injection USP OR gentamicin sulfate injection solution concentrate 5mg.kg IV q24h; amikacin sulfate injection USP 20 mg/kg IV q24h, Linezolid or Vancomycin (per institutional guidelines) will be available for MRSA coverage., tobramycin nebulization
Drug · Device
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
8
States / cities
San Mateo, California • Gainesville, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2017 · Synced Jul 21, 2026, 8:53 PM EDT
Terminated Phase 3 Interventional Results available

A Safety and Tolerability Study of Doripenem Compared With Cefepime in Hospitalized Children With Bacterial Pneumonia

NCT01110421
View directory record Official record
Conditions
Pneumonia, Bacterial, Community-Acquired Infections, Nosocomial Infection, Pneumonia, Ventilator-Associated
Interventions
Cefepime placebo, Cefepime, Doripenem, Doripenem placebo, Amoxicillin/clavulanate potassium
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
3 Months to 18 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
4
States / cities
Little Rock, Arkansas • Cleveland, Ohio • Toledo, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2014 · Synced Jul 21, 2026, 8:53 PM EDT
Completed Phase 3 Interventional Results available

Imipenem/Cilastatin-XNW4107 Versus Imipenem/Cilastatin/Relebactam for Treatment of Participants With Bacterial Pneumonia (XNW4107-302, REITAB-2)

NCT05204563
View directory record Official record
Conditions
Hospital Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia
Interventions
Combination of Imipenem/Cilastatin and XNW4107, Imipenem/Cilastatin/Relebactam
Drug
Lead sponsor
Evopoint Biosciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
10
States / cities
Denver, Colorado • Hartford, Connecticut • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Jul 21, 2026, 8:53 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults

NCT02168946
View directory record Official record
Conditions
Urinary Tract Infection Complicated, Acute Pyelonephritis, Hospital Acquired Bacterial Pneumonia, Ventilator-associated Bacterial Pneumonia, Bacteremia, Abdominal Infection
Interventions
Vabomere, Best Available Therapy
Drug
Lead sponsor
Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
20
States / cities
Hartford, Connecticut • Tampa, Florida • Augusta, Georgia + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2019 · Synced Jul 21, 2026, 8:53 PM EDT